Bharat Biotech submitted data of the Phase 2/3 trials of COVID-19 vaccine Covaxin for use in children under 18 years of ageto the Central Drugs Standard Control Organisation.
WHO further delays Covaxin clearance over technical queries indiatvnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from indiatvnews.com Daily Mail and Mail on Sunday newspapers.
WHO s emergency use authorization to Covaxin expected soon: MoS Health Dr Bharati Pravin Pawar india.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from india.com Daily Mail and Mail on Sunday newspapers.
Bharat Biotech has successfully completed its trials of Phase 2/3 Covid 19 vaccine, Covaxin for use in children under the age of 18, and is scheduled to submit the data to the DCGI by next week said Krishna Ella, Chairman and Managing Director of Bharat Biotech International Ltd. He told reporters that Covaxin manufacturing will reach 55 million doses in October, up from 35
Bharat Biotech completes phase 2/3 trials of Covaxin for children under 18 years asianage.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from asianage.com Daily Mail and Mail on Sunday newspapers.